vs

Side-by-side financial comparison of Commercial Bancgroup, Inc. (CBK) and NEKTAR THERAPEUTICS (NKTR). Click either name above to swap in a different company.

Commercial Bancgroup, Inc. is the larger business by last-quarter revenue ($23.1M vs $21.8M, roughly 1.1× NEKTAR THERAPEUTICS). Commercial Bancgroup, Inc. runs the higher net margin — 41.3% vs -165.4%, a 206.8% gap on every dollar of revenue.

Commercial Bancgroup, Inc. operates as a U.S. regional bank holding company that provides a full suite of retail and commercial banking products and services to individual consumers, small and medium-sized businesses, and local institutional clients. Its core offerings include deposit accounts, lending solutions, wealth management, and tailored financial advisory services for regional markets.

Nektar Therapeutics is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California. The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances, which improves drug characteristics like retention and solubility. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, e...

CBK vs NKTR — Head-to-Head

Bigger by revenue
CBK
CBK
1.1× larger
CBK
$23.1M
$21.8M
NKTR
Higher net margin
CBK
CBK
206.8% more per $
CBK
41.3%
-165.4%
NKTR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBK
CBK
NKTR
NKTR
Revenue
$23.1M
$21.8M
Net Profit
$9.5M
$-36.1M
Gross Margin
Operating Margin
-126.9%
Net Margin
41.3%
-165.4%
Revenue YoY
-25.3%
Net Profit YoY
9.7%
-596.9%
EPS (diluted)
$0.69
$-4.67

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBK
CBK
NKTR
NKTR
Q1 26
$23.1M
Q4 25
$23.5M
$21.8M
Q3 25
$22.8M
$11.8M
Q2 25
$11.2M
Q1 25
$10.5M
Q4 24
$29.2M
Q3 24
$24.1M
Q2 24
$23.5M
Net Profit
CBK
CBK
NKTR
NKTR
Q1 26
$9.5M
Q4 25
$9.9M
$-36.1M
Q3 25
$9.5M
$-35.5M
Q2 25
$-41.6M
Q1 25
$-50.9M
Q4 24
$7.3M
Q3 24
$-37.1M
Q2 24
$-52.4M
Gross Margin
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
72.7%
Q3 24
81.6%
Q2 24
58.5%
Operating Margin
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
-126.9%
Q3 25
53.8%
-268.6%
Q2 25
-324.2%
Q1 25
-425.8%
Q4 24
49.2%
Q3 24
-142.4%
Q2 24
-211.9%
Net Margin
CBK
CBK
NKTR
NKTR
Q1 26
41.3%
Q4 25
42.2%
-165.4%
Q3 25
41.4%
-301.3%
Q2 25
-372.2%
Q1 25
-486.4%
Q4 24
24.9%
Q3 24
-153.6%
Q2 24
-222.9%
EPS (diluted)
CBK
CBK
NKTR
NKTR
Q1 26
$0.69
Q4 25
$0.72
$-4.67
Q3 25
$0.77
$-1.87
Q2 25
$-2.95
Q1 25
$-0.24
Q4 24
$-2.07
Q3 24
$-2.66
Q2 24
$-3.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBK
CBK
NKTR
NKTR
Cash + ST InvestmentsLiquidity on hand
$15.1M
Total DebtLower is stronger
$118.2M
Stockholders' EquityBook value
$89.8M
Total Assets
$2.3B
$280.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
$15.1M
Q3 25
$154.8M
$41.0M
Q2 25
$43.0M
Q1 25
$38.9M
Q4 24
$44.3M
Q3 24
$30.1M
Q2 24
$27.9M
Total Debt
CBK
CBK
NKTR
NKTR
Q1 26
$118.2M
Q4 25
$166.8M
Q3 25
$100.1M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
$89.8M
Q3 25
$245.2M
$85.1M
Q2 25
$-24.2M
Q1 25
$13.7M
Q4 24
$60.7M
Q3 24
$48.9M
Q2 24
$79.7M
Total Assets
CBK
CBK
NKTR
NKTR
Q1 26
$2.3B
Q4 25
$2.3B
$280.4M
Q3 25
$2.2B
$301.3M
Q2 25
$207.5M
Q1 25
$256.2M
Q4 24
$303.9M
Q3 24
$308.0M
Q2 24
$343.3M
Debt / Equity
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
Q3 25
0.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBK
CBK
NKTR
NKTR
Operating Cash FlowLast quarter
$-65.0M
Free Cash FlowOCF − Capex
$-65.0M
FCF MarginFCF / Revenue
-298.0%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-208.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
$-65.0M
Q3 25
$28.0M
$-48.8M
Q2 25
$-45.7M
Q1 25
$-49.1M
Q4 24
$-46.2M
Q3 24
$-43.9M
Q2 24
$-37.7M
Free Cash Flow
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
$-65.0M
Q3 25
$26.5M
$-48.9M
Q2 25
$-45.8M
Q1 25
$-49.1M
Q4 24
$-46.6M
Q3 24
$-44.6M
Q2 24
$-37.9M
FCF Margin
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
-298.0%
Q3 25
115.8%
-414.5%
Q2 25
-409.6%
Q1 25
-469.0%
Q4 24
-159.9%
Q3 24
-184.9%
Q2 24
-161.3%
Capex Intensity
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
0.1%
Q3 25
6.7%
1.0%
Q2 25
0.3%
Q1 25
0.0%
Q4 24
1.6%
Q3 24
2.8%
Q2 24
0.8%
Cash Conversion
CBK
CBK
NKTR
NKTR
Q1 26
Q4 25
Q3 25
2.96×
Q2 25
Q1 25
Q4 24
-6.36×
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBK
CBK

Net Interest Income$20.5M89%
Noninterest Income$2.6M11%

NKTR
NKTR

Segment breakdown not available.

Related Comparisons